New Cancer Immunotherapy Agents in Development Presentation Application
Important Application Dates & Timeline
|June 9, 2016||Submission Period Opened*|
|August 8, 2016||Submission Period Closed|
|August 28, 2016||Acceptance Notifications Sent Out|
|September 6, 2016||Acceptance of Notification Due|
|November 9, 2016||New Cancer Immunotherapy Agents in Development Program|
|*Application submission for this program did not qualify as a 31st Annual Meeting abstract submission.|
Presentation Application Information
Submission Period & Details
Presentation applications were accepted through Monday, August 8, 2016 at 11:59 p.m. EDT. Companies who are developing new cancer immunotherapy agents were welcome to submit an application describing their new agent.
Applications include a questionnaire on your new therapy and its target. Target examples include LAG3, Tim-3, 4-1BB, OX40, CD40, IDO, GITR, ICOS, CSF-1R, CCR4, T Cell Bispecific, CAR-T, TCR-T, vaccines and more.
- Content within submissions should be publicly available to present by November 9, 2016
- The agents within the submission is not required to be new, but preference will be given to data that has not been presented elsewhere or has had significant changes to the submission since last being presented or published
- The target molecule needs to have a primary mechanism of action that is considered an immunotherapy
- It is preferable that submissions include clinical data from a primary immunotherapy agent beyond PD-1, PD-L1, and CTLA-4, in combination. Application selection preference will be given in the following order:
- Combination therapy with available clinical data
- Combination therapy with available pre-clinical data
- Monotherapy with available clinical data
- Monotherapy with available pre-clinical data
- Accepted applicants will be invited to speak during SITC's New Cancer Immunotherapy Agents in Development program on Wednesday, November 9, 2016
- All accepted presentations will be included in the program's post meeting summary which will be published in the Journal for ImmunoTherapy of Cancer, the Society's own global, open access, peer-reviewed journal
Frequently Asked Questions
Can this information also be submitted as an abstract for SITC's 31st Annual Meeting?
Yes, it can. However, submission of this application for this program did not qualify as a 31st Annual Meeting abstract submission.
Can a company submit more than one application?
Yes, a company may submit more than one application. However, the review committee will review all applications and may choose to accept only one from each company to allow for diverse representation.
Questions? Contact SITC.